专用腋窝混合18F-FDG PET/MRI在临床淋巴结阳性乳腺癌腋窝淋巴结分期中的附加价值:可行性研究
本研究纳入12例临床淋巴结阳性乳腺癌患者,行腋窝超声和专用腋窝混合18F-FDG PET/MRI,其中9例另行全身PET/CT。专用腋窝PET/MRI与PET/CT在原发肿瘤及最高FDG摄取腋窝淋巴结的SUVmax上无显著差异;与标准影像相比,专用腋窝PET/MRI使淋巴结状态发生改变的比例分别为超声40%、T2加权MRI 75%、增强MRI 40%、PET/CT 22%。作者认为在诊断流程中加入专用腋窝18F-FDG混合PET/MRI可能改善腋窝淋巴结分期诊断性能。
要点
- 专用腋窝混合18F-FDG PET/MRI在临床淋巴结阳性乳腺癌中可行。
- 专用腋窝PET/MRI与PET/CT的原发肿瘤及最高FDG摄取腋窝淋巴结SUVmax无显著差异。
- 与超声、MRI、PET/CT相比,专用腋窝PET/MRI使淋巴结状态发生改变的比例分别为40%、75%、40%、22%。
核心结论
- 在诊断流程中加入专用腋窝18F-FDG混合PET/MRI可能改善临床淋巴结阳性乳腺癌患者的腋窝淋巴结分期诊断性能。
研究设计与样本
- 可行性研究,纳入12例临床淋巴结阳性乳腺癌患者,均行腋窝超声和专用腋窝混合18F-FDG PET/MRI,其中9例另行全身PET/CT。
主要发现
- 根据专用腋窝混合PET/MRI结果,7例诊断为N1、4例N2、1例N3。
- 专用腋窝PET/MRI与PET/CT的原发肿瘤平均SUVmax分别为9.0(±5.0)与8.6(±5.7),p=0.678,无显著差异。
- 专用腋窝PET/MRI与PET/CT的最高FDG摄取腋窝淋巴结平均SUVmax分别为7.8(±5.3)与7.7(±4.3),p=0.767,无显著差异。
- 与标准影像相比,专用腋窝混合PET/MRI使淋巴结状态发生改变的比例为:超声40%、T2加权MRI 75%、增强MRI 40%、PET/CT 22%。
关键数值与推荐
- 专用腋窝混合PET/MRI阳性的腋窝淋巴结定义为中等至非常强烈FDG摄取的淋巴结。
- 可疑腋窝淋巴结数目分为N0(0枚)、N1(1-3枚)、N2(4-9枚)、N3(≥10枚)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the feasibility and potential added value of dedicated axillary 18F-FDG hybrid PET/MRI, compared to standard imaging modalities (i.e. ultrasound [US], MRI and PET/CT), for axillary nodal staging in clinically node-positive breast cancer. METHODS: Twelve patients with clinically node-positive breast cancer underwent axillary US and dedicated axillary hybrid 18F-FDG PET/MRI. Nine of the 12 patients also underwent whole-body PET/CT. Maximum standardized uptake values (SUVmax) were measured for the primary breast tumor and the most FDG-avid axillary lymph node. A positive axillary lymph node on dedicated axillary hybrid PET/MRI was defined as a moderate to very intense FDG-avid lymph node. The diagnostic performance of dedicated axillary hybrid PET/MRI was calculated by comparing quantitative and its qualitative measurements to results of axillary US, MRI and PET/CT. The number of suspicious axillary lymph nodes was subdivided as follows: N0 (0 nodes), N1 (1-3 nodes), N2 (4-9 nodes) and N3 (≥ 10 nodes). RESULTS: According to dedicated axillary hybrid PET/MRI findings, seven patients were diagnosed with N1, four with N2 and one with N3. With regard to mean SUVmax, there was no significant difference in the primary tumor (9.0 [±5.0] vs. 8.6 [±5.7], p = 0.678) or the most FDG-avid axillary lymph node (7.8 [±5.3] vs. 7.7 [±4.3], p = 0.767) between dedicated axillary PET/MRI and PET/CT. Compared to standard imaging modalities, dedicated axillary hybrid PET/MRI resulted in changes in nodal status as follows: 40% compared to US, 75% compared to T2-weighted MRI, 40% compared to contrast-enhanced MRI, and 22% compared to PET/CT. CONCLUSIONS: Adding dedicated axillary 18F-FDG hybrid PET/MRI to diagnostic work-up may improve the diagnostic performance of axillary nodal staging in clinically node-positive breast cancer patients.
引用
- van Nijnatten TJA, Goorts B, Vöö S, et al. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study. Eur J Nucl Med Mol Imaging. 2017. PMID: 28905091. doi:10.1007/s00259-017-3823-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。